Aprea Therapeutics (APRE) executive compensation, 2026 proxy

Oren Gilad, Ph.D., President and Chief Executive Officer, was paid $657,259 in 2025, down 14% from $760,091 the year before.

Filed
April 30, 2026
Annual meeting
June 16, 2026
Pay year
2025
Named executives
2
CEO total pay
$657,259-14% vs prior year
CEO pay in equity
9%$58,373 in awards
CEO Base Salary
$594,880Increased 4% for 2025
CEO Target Bonus
50%Percentage of base salary
CFO Base Salary
$454,272Increased 4% for 2025
CFO Target Bonus
40%Percentage of base salary

How Ph.D. was paid

$657,259 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary91%Stock awards2%Option awards7%All other compensation1%

Named executive officers

ExecutiveTotal
Oren Gilad, Ph.D.President and Chief Executive Officer$657,259
John P. HamillChief Financial Officer$490,652

What changed and why

  • $760KCEO total compensation decreased from $760,091 in 2024 to $657,259 in 2025.
  • 4.0%CEO base salary increased by 4.0% to $594,880 for fiscal year 2025.
  • 4.0%Both named executive officers received 4.0% market-based base salary increases for 2025.
  • Equity awards in 2025 consisted of time-vesting stock options and restricted stock units.
  • No perquisites were provided to named executive officers during fiscal year 2025.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.